Morgan Stanley
ESLA icon

Morgan Stanley’s Estrella Immunopharma ESLA Stock Holding History

Morgan Stanley’s Portfolio ESLA Stock Details ESLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1 Sell
1
-11,096
-100% -$12.8K ﹤0.01% 8277
2025
Q4 		$17.3K Buy
+11,097
New +$21K ﹤0.01% 6741

Other funds holding ESLA

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return

Morgan Stanley's ESLA Position: Q1 2026 in Review

Morgan Stanley reduced its Estrella Immunopharma (ESLA) stake by 100% in Q1 2026, selling an estimated $12.8K and leaving 1 share worth $1. The position accounts for ﹤0.01% of the portfolio, ranked #8277.

Morgan Stanley first reported a position in ESLA in Q4 2025 and has held it in 2 quarters since. The position peaked at $17.3K in Q4 2025. 16 funds tracked by Wall St. Rank hold ESLA as of Q1 2026.

  • Morgan Stanley held 1 share of Estrella Immunopharma worth $1 as of Q1 2026.
  • Morgan Stanley sold 11,096 Estrella Immunopharma shares in Q1 2026, an estimated $12.8K.
  • Estrella Immunopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #8277 holding.
  • Morgan Stanley first reported a position in Estrella Immunopharma in Q4 2025 and has held it in 2 quarters since.
  • Morgan Stanley's Estrella Immunopharma position peaked at $17.3K in Q4 2025.
  • 16 funds tracked by Wall St. Rank held Estrella Immunopharma as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.